P-BCMA-101
Relapsed/Refractory Multiple Myeloma
Phase 1/2Legacy Program
Key Facts
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 1/2
Status
Legacy Program
Company
About Poseida Therapeutics
Poseida Therapeutics was a San Diego-based biotech focused on developing next-generation cell and gene therapies with its non-viral engineering platforms. Its core strategy centered on overcoming the limitations of viral vectors to create CAR-T products with a high proportion of stem cell memory T cells for enhanced persistence and potency. The company advanced a pipeline of autologous and allogeneic CAR-T candidates targeting hematological malignancies and solid tumors. Its significant technological achievements culminated in its acquisition by Roche in 2024, validating its platform and providing a path for accelerated development.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| Linvoseltamab | Regeneron | Phase 3 |
| Blenrep (belantamab mafodotin) | GSK | Phase III |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| HDP-101 | Heidelberg Pharma | Phase I/IIa |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| CT053 | CARsgen Therapeutics | Phase Ib/II |
| CT059 | CARsgen Therapeutics | Phase I |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| ABBV-383 | AbbVie | Phase 1 |
| bri-cel (BAY 2413334) | Bayer | Phase I |